| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807708 | GALDERMA LABS LP | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
Jul, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470871 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(1 year, 7 months from now) | |
| US8227507 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(1 year, 7 months from now) | |
| US9498465 | GALDERMA LABS LP | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(9 years from now) | |
| US9084778 | GALDERMA LABS LP | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(9 years from now) | |
Aklief is owned by Galderma Labs Lp.
Aklief contains Trifarotene.
Aklief has a total of 5 drug patents out of which 0 drug patents have expired.
Aklief was authorised for market use on 04 October, 2019.
Aklief is available in cream;topical dosage forms.
Aklief can be used as topical treatment of acne vulgaris, treatment of acne vulgaris, method of activating rargamma receptor.
Drug patent challenges can be filed against Aklief from 05 October, 2023.
The generics of Aklief are possible to be released after 30 May, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 04, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 05 October, 2023
Market Authorisation Date: 04 October, 2019
Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris; Treatment of acne vulgaris
Dosage: CREAM;TOPICAL
AKLIEF family patents
